Safety of biweekly α1-antitrypsin treatment in the RAPID programme

Eur Respir J. 2018 Nov 29;52(5):1800897. doi: 10.1183/13993003.00897-2018. Print 2018 Nov.

Abstract

Administration of 120 mg·kg−1 α1-antitrypsin on a biweekly basis was safe and well tolerated http://ow.ly/CVbz30lUBum

Trial registration: ClinicalTrials.gov NCT00261833 NCT00670007.

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Female
  • Humans
  • Infusions, Intravenous
  • Lung / physiopathology
  • Male
  • Middle Aged
  • Pulmonary Emphysema / drug therapy*
  • Pulmonary Emphysema / etiology
  • Pulmonary Emphysema / physiopathology
  • Treatment Outcome
  • alpha 1-Antitrypsin / administration & dosage*
  • alpha 1-Antitrypsin / adverse effects
  • alpha 1-Antitrypsin Deficiency / complications
  • alpha 1-Antitrypsin Deficiency / drug therapy*
  • alpha 1-Antitrypsin Deficiency / physiopathology

Substances

  • alpha 1-Antitrypsin

Associated data

  • ClinicalTrials.gov/NCT00261833
  • ClinicalTrials.gov/NCT00670007